MoCRA Check-In: EAS Consulting's John Bailey On Proposed Cosmetics Office Move
Executive Summary
John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group and former director of the US FDA's cosmetics office, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the Modernization of Cosmetic Regulations Act of 2022. Here he discusses the FDA's plan to move cosmetics regulation out of CFSAN and into the Office of the Chief Scientist.
You may also be interested in...
MoCRA Check-In: FDA Guidance Urgently Needed As Year-End Compliance Deadlines Loom
John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.
Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions
After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.
Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.